Sarepta Therapeutics Inc (SRPT) USD0.0001
Share news, reports & tips
23 December 2019 09:28
(Sharecast News) - Switzerland's Roche has bought the rights to launch and sell one of Sarepta Therapeutics's gene therapy treatments for Duchenne muscular dystrophy outside of the States, sending...
10 October 2019 19:16
(Sharecast News) - Analysts at RBC reiterated their recommendation to 'buy' shares of Sarepta, expressing confidence in the efficacy of the gene therapy specialist's muscular distrophy...
20 August 2019 15:24
(Sharecast News) - Shares of Wall Street biotechnology darling Sarepta Therapeutics came under sharp selling pressure after America's drug safety watchdog rejected the company's petition for...
27 March 2019 12:24
(Sharecast News) - Summit Therapeutics on Wednesday reported that it swung to an annual profit following a leap in revenues attributed to a collaboration agreement with Sarepta Therapeutics.
Company announcements Announcements
No company announcements about Sarepta Therapeutics Inc USD0.0001 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2020. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.